The European Medicines Agency has recommended granting marketing authorization for a new hybrid formulation of buprenorphine as a substitution treatment of opioid drug dependence. Buprenorphine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback